Physical Activity Program for the Survival of Elderly Patients With Lymphoma: Study Protocol for Randomized Phase 3 Trial
Authors:
- Jonas DubuJDJonas Dubu
- Sébastien BoyasSBSébastien Boyas
- Virginie RolandVRVirginie Roland
- Sébastien LandrySLSébastien Landry
- Anne-Lise SeptansASAnne-Lise Septans
- Magali BalavoineMBMagali Balavoine
- Hugues BourgeoisHBHugues Bourgeois
- Yoann PointreauYPYoann Pointreau
- Fabrice DenisFDFabrice Denis
- Christophe LetellierCLChristophe Letellier
- Katell Le DûKDKatell Le Dû
Open Access
- 24 November 2022
- journal article
- research article
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (11) , e40969
Abstract
Background: The practice of regular physical activity can reduce the incidence of certain cancers (colon, breast, and prostate) and improve overall survival after treatment by reducing fatigue and the risk of relapse. This impact on survival has only been demonstrated in active patients with lymphoma before and after treatment. As poor general health status reduces the chances of survival and these patients are most likely to also have sarcopenia, it is important to be able to improve their physical function through adapted physical activity (APA) as part of supportive care management. Unfortunately, APA is often saved for patients with advanced blood cancer. As a result, there is a lack of data regarding the impact of standardized regular practice of APA and concomitant chemotherapy as first-line treatment on lymphoma survival.Objective: This study aimed to assess the impact of a new and open rehabilitation program suitable for a frail population of patients treated for diffuse large B-cell lymphoma (DLBCL).Methods: PHARAOM (Physical Activity Program for the Survival of Elderly Patients with Lymphoma) is a phase 3 randomized (1:1) study focusing on a frail population of patients treated for DLBCL. The study will include 186 older adult patients with DLBCL (aged >65 years) receiving rituximab and chemotherapy. Overall, 50% (93/186) of patients (investigational group) will receive APA along with chemotherapy, and they will be supervised by a dedicated qualified kinesiologist. The APA program will include endurance and resistance training at moderate intensity 3 times a week during the 6 months of chemotherapy. The primary end point of this study will be event-free survival of the patients. The secondary end points will include the overall survival, progression-free survival, prevalence of sarcopenia and undernutrition, and patients' quality of life. This study will be conducted in accordance with the principles of the Declaration of Helsinki.Results: Recruitment, enrollment, and data collection began in February 2021, and 4 participants have been enrolled in the study as of July 2022. Data analysis will begin after the completion of data collection. Future outcomes will be published in peer-reviewed health-related research journals and presented at national congress, and state professional meetings. This publication is based on protocol version 1.1, August 3, 2020.Conclusions: The PHARAOM study focuses on highlighting the benefits of APA intervention on survival during the period of first-line treatment of patients with DLBCL. This study could also contribute to our understanding of how an APA program can reduce complications such as sarcopenia in patients with lymphoma and improve their quality of life. By documenting the prevalence and relationship between sarcopenia and exercise load, we might be able to help physicians plan better interventions in the care of patients with DLBCL.Trial Registration: ClinicalTrials.gov NCT04670029; https://clinicaltrials.gov/ct2/show/NCT04670029International Registered Report Identifier (IRRID): DERR1-10.2196/40969Keywords
This publication has 72 references indexed in Scilit:
- Implementing the Exercise Guidelines for Cancer SurvivorsJournal of Supportive Oncology, 2012
- Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinomaEuropean Journal of Cancer, 2010
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Monitoring Exercise Intensity During Resistance Training Using the Session RPE ScaleJournal of Strength & Conditioning Research, 2004
- The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigueJournal of Psychosomatic Research, 1995
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily LivingThe Gerontologist, 1969